Patents by Inventor Hermann Kunzer

Hermann Kunzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
    Publication number: 20080200519
    Abstract: The present invention relates to the compounds of formula I, processes for their production and their use as anti-inflammatory agents.
    Type: Application
    Filed: February 15, 2008
    Publication date: August 21, 2008
    Inventors: Markus BERGER, Hartmut Rehwinkel, Heike Schacke, Ekkehard May, Werner Skuballa, Hermann Kunzer
  • 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS
    Patent number: 6780855
    Abstract: This invention describes the new 11&bgr;-halogen-7&agr;-substituted estratrienes of general formula I in which R11 is a fluorine or chlorine atom, and the other substituents have the meanings that are explained in more detail in the description. The compounds have antiestrogenic properties or tissue-selective estrogenic properties and are suitable for the production of pharmaceutical agents.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: August 24, 2004
    Assignee: Schering Aktiengesellschaft
    Inventors: Rolf Bohlmann, Nikolaus Heinrich, Helmut Hofmeister, Jorg Kroll, Hermann Kunzer, Gerhard Sauer, Ludwig Zorn, Karl-Heinrich Fritzemeier, Monika Lessl, Rosemarie Lichtner, Yukishige Nishino, Karsten Parczyk, Martin Schneider
  • 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS
    Publication number: 20030069434
    Abstract: This invention describes the new 11&bgr;-halogen-7&agr;-substituted estratrienes of general formula I 1
    Type: Application
    Filed: December 2, 1999
    Publication date: April 10, 2003
    Inventors: ROLF BOHLMANN, NIKOLAUS HEINRICH, HELMUT HOFMEISTER, JORG KROLL, HERMANN KUNZER, GERHARD SAUER, LUDWIG ZORN, KARL-HEINRICH FRITZEMEIER, MONIKA LESSL, ROSEMARIE LICHTNER, YUKISHIGE NISHINO, KARSTEN PARCZYK, MARTIN SCHNEIDER
  • 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7.alpha.-(.xi.-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
    Patent number: 5986115
    Abstract: This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids.The new compounds represent compounds with very strong antiestrogenic action.The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: November 16, 1999
    Assignee: Schering AG
    Inventors: Rolf Bohlmann, Dieter Bittler, Josef Heindl, Nikolaus Heinrich, Helmut Hofmeister, Hermann Kunzer, Gerhard Sauer, Christa Hegele-Hartung, Rosemarie Lichtner, Yukishige Nishino, Karsten Parczyk, Martin Schneider
  • 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7.alpha.-(.xi.-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
    Patent number: 5866560
    Abstract: This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids.The new compounds represent compounds with very strong antiestrogenic action.The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: February 2, 1999
    Assignee: Schering AG
    Inventors: Rolf Bohlmann, Dieter Bittler, Josef Heindl, Nikolaus Heinrich, Helmut Hofmeister, Hermann Kunzer, Gerhard Sauer, Christa Hegele-Hartung, Rosemarie Lichtner, Yukishige Nishino, Karsten Parczyk, Martin Schneider
  • Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents
    Patent number: 5807899
    Abstract: This invention describes the new triphenylethylenes of general formula I ##STR1## in which n means an integer from 1 to 10,R' means a sulfur-containing organic radical,R" means a hydrogen atom, an iodine atom or a hydroxy groups,E means a hydrogen atom,G means a hydrogen atom orE and G together mean a methylene bridge.The new compounds have strong antiestrogenic properties and are suitable for the production of pharmaceutical agents, for example for treating breast cancer.
    Type: Grant
    Filed: July 5, 1996
    Date of Patent: September 15, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Rolf Bohlmann, Joseph Heindl, Hermann Kunzer, Yukishige Nishino, Karsten Parczyk, Martin Schneider
  • 11.beta.-substituted 14,17-ethanoestratrienes, process for their production and their use as pharmaceutical agents
    Patent number: 5502046
    Abstract: The invention relates to 11 .beta.-substituted 14,17-ethanoestratrienes of the general formula 1 ##STR1## where R.sup.1, R.sup.2 and R.sup.3 are defined in the specification. The compound have antiestrogenic activity and are, therefore, useful for the treatment of estrogen dependent disorders.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: March 26, 1996
    Assignee: Schering Aktiengesellschaft
    Inventors: Rolf Bohlmann, Hermann Kunzer, Hans-Peter Muhn-Seipoldy, Yukishige Nishino, Martin Schneider
  • 14,17.alpha.-etheno- and -ethanoestratrienes, processes for the preparation of these compounds, as well as their use for the production of medicinal agents
    Patent number: 5145847
    Abstract: Disclosed are novel 14,17.alpha.-etheno- and -ethanoestratrienes according to general Formula I ##STR1## wherein X is a --CH.sub.2 --CH.sub.2 or ##STR2## R.sup.1 is a hydrogen atom, a C.sub.1 - to C.sub.15 -acyl, benzoyl, C.sub.1 - to C.sub.15 -alkyl, C.sub.3 - to C.sub.9 -cycloalkyl or alkylcycloalkyl group, andR.sup.2 is the grouping ##STR3## wherein R.sup.3 and R.sup.4 independently of each other mean a hydrogen atom or a straight-chain or branched, optionally partially or completely fluorinated C.sub.1 -C.sub.8 -alkyl group,a process for their preparation, pharmaceutical preparations containing these compounds, as well as their use for the production of medicinal agents.The novel compounds exhibit strong antiestrogenic efficacy.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: September 8, 1992
    Assignee: Schering Aktiengesellschaft
    Inventors: Rolf Bohlmann, Hermann Kunzer, Rudolf Wiechert, David Henderson, Martin Schneider, Yukishige Nishino